Caraway Therapeutics, Inc.
Biotechnology Research
Cambridge, MA 1,978 followers
a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Precision Medicines for CNS and Rare Diseases
About us
A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
- Website
-
http://carawaytx.com/
External link for Caraway Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
- Type
- Privately Held
- Specialties
- Small molecule therapeutics that boost cellular clearance pathways to restore balance
Locations
-
Primary
Get directions
300 Technology Square
Suite 201
Cambridge, MA 02139, US
Employees at Caraway Therapeutics, Inc.
-
Jayhong Chong
Senior Director at Caraway Therapeutics, a subsidiary of Merck & Co. Inc. (Rahway, NJ)
-
J. Stefan Kaczmarek
Executive Director at Caraway Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
-
Thomas Lee
Head of Chemistry at Caraway Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
-
Donato del Camino
Vice President Research, Caraway Therapeutics